Диссертация (1174336), страница 32
Текст из файла (страница 32)
Genet. – 1988. – Vol. 29,№3. – P. 581-594.160. Jabłońska-Trypuć, A. Matrix metalloproteinases (MMPs), the mainextracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancerdrugs / A. Jabłońska-Trypuć, M. Matejczyk, S. Rosochacki // Enzyme Inhib. Med.Chem. – 2016. – Vol. 31, Suppl. 1. – P. 177-183.161. Jentsch, T.J. Chloride channel diseasesresulting from impairedtransepithelial transport or vesicular function / T.J. Jentsch, T. Maritzen, A.A. Zdebik// J. Clin.
Invest. – 2005. – Vol. 115, № 8. – P. 2039-2046.162. Johansson, N. Matrix metalloproteinases in tumor invasion / N.Johansson, M. Ahonen, V.M. Kähäri // Cell Mol. Life Sci. – 2000. – Vol. 57, № 5. –P. 5-15.163. Johansson, N. Matrix metalloproteinases in tumor invasion / N.Johansson, M. Ahonen, V.M. Kähäri // Cell Mol. Life Sci. – 2000. – Vol. 57, № 5.
–P. 5-15.164. Kadler, K.E. Collagen fibrillogenesis: fibronectin, integrins, and minorcollagens as organizers and nucleators / K.E. Kadler, A. Hill, E.G. Canty-Laird // Curr.Opin. Cell Biol. – 2008. – Vol. 20, № 5. – P. 495-501.165. Kivirikko, K.I. Collagens and their abnormalities in a wide spectrum ofdiseases / K.I. Kivirikko // Ann. Med. – 1993.
– Vol. 25, № 2. – P. 113-126.205166. Kolekar, S. Bullous lungs: diverse aetiology / S. Kolekar, P. Sandaram //Postgrad. Med. J. – 2002. – Vol. 78, № 925. – P. 689-692.167. Lièvre, A. Genetic polymorphisms of MMP1, MMP3 and MMP7 genepromoter and risk of colorectal adenoma / A. Lièvre, J. Milet, J. Carayol // BMCCancer.
– 2006. – Vol. 6. – P. 270.168. Linkage of Marfan syndrome and a phenotypically related disorder to twodifferent fibrillin genes / B. Lee, M. Godfrey, E. Vitale, H. Hori, M.G. Mattei, M.Sarfarazi, P. Tsipouras, F. Ramirez, D.W. Hollister // Nature. – 1991. – Vol. 352, №6333. – P. 330-334.169. Lucas, R.V. Jr. The floppy mitral valve / R.V. Jr.
Lucas, J.E. Edwards //Curr ProblCardiol. – 1982. – Vol. 7. – P. 1-48.170. Lung findings on thoracic high-resolution computed tomography inpatients with ankylosing spondylitis. Correlations with disease duration, clinicalfindings and pulmonary function testing / A. El Maghraoui, S. Chaouir, A. Abid, A.Bezza, F. Tabache, L. Achemlal, A. Abouzahir, D. Ghafir, V. Ohayon, M.I. Archane// Clin. Rheumatol. – 2004.
– Vol. 23, № 2. – P. 123-128.171. Macrophage elastase kills bacteria within murine macrophages / A.M.Houghton, W.O. Hartzell, C.S. Robbins, F.X. Gomis-Ruth, S.D. Shapiro // Nature. –2009. – Vol. 460, № 7255. – P. 637-641.172. Management of acute respiratory failure in interstitial lung diseases:overview and clinical insights / P. Faverio, F. De Giacomi, L. Sardella, G. Fiorentino,M.
Carone, F. Salerno, J. Ora, P. Rogliani, G. Pellegrino, G.F. Sferrazza Papa, F. Bini,B.D. Bodini, G. Messinesi, A. Pesci, A. Esquinas // BMC Pulm Med. – 2018. – Vol.18 (1). – Р. 70.173. Management of Cystic Fibrosis Related Diabetes Mellitus // Report of theUK Cystic Fibrosis Trust Diabetes Working Group. – UK: CF Trust, 2004.
– 84 р.174. Marshall, B.C. Cystic Fibrosis Foundation Patient Registry. Annual DataReport. / B.C. Marshall. – Bethesda, Maryland, 2017. – 6 р.175. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis / C.M.Yamashita, L. Dolgonos, R.L. Zemans, S.K. Young, J. Robertson, N. Briones, T.206Suzuki, M.N. Campbell, J. Gauldie, D.C. Radisky, D.W. Riches, G. Yu, N. Kaminski,C.A. McCulloch, G.P. Downey // Am. J. Pathol. – 2011. – Vol. 179, № 4. –Р.17331745.176.
Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoterpolymorphisms are associated with carotid artery stenosis / G. Ghilardi, M.A. Biondi,M. DeMonti, O. Turri, E. Guagnellini, R. Scorza // Stroke. – 2002. – Vol. 33, № 10.– P. 2408-2412.177. Matrixmetalloproteinase-3andvitaminDreceptorgeneticpolymorphisms, and their interactions with occupational exposure in lumbar discdegeneration / H.Y.
Yuan, Y. Tang, Y.X. Liang, L. Lei, G.B. Xiao, S. Wang, Z.L. Xia// J. Occup. Health. – 2010. – Vol. 52, № 1. – P. 23-30.178. Matrix metalloproteinase-7 degrades all insulin-like growth factor bindingproteins and facilitates insulin-like growth factor bioavailability / M. Nakamura, S.Miyamoto, H. Maeda, G. Ishii, T. Hasebe, T. Chiba, M. Asaka, A. Ochiai // Biochem.Biophys. Res. Commun. – 2005. – Vol. 333, № 3. – P. 1011-1016.179. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonaryfibrosis / V.J.
Craig, L. Zhang, J.S. Hagood, C.A. Owen // Am. J. Respir. Cell Mol.Biol. – 2015. – Vol. 53, № 5. – P. 585-600.180. MBL2 polymorphisms screening in a regional Italian CF center / C.Trevisiol, M. Boniotto, L. Giglio, F. Poli, M. Morgutti, S. Crovella // J. Cyst. Fibros.– 2005. – Vol. 4, № 3. – P. 189-191.181. McKone, E.F. CFTR genotype as a predictor of prognosis in cysticfibrosis / E.F. McKone, C.H.
Goss, M.L. Aitken // Chest. – 2006. – Vol. 130, № 5. –P. 1441-1447.182. Membrane-boundmatrixmetalloproteinase-8onactivatedpolymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistantcollagenase and serpinase / C.A. Owen, Z. Hu, C. Lopez-Otin, S.D. Shapiro // J.Immunol. – 2004.
– Vol. 172, № 12. – P. 7791-7803.183. Molecular biology of the cell. – 4th edition. / B. Alberts, A. Johnson, J.Lewis, M. Raff, R. Roberts, P. Walter // Garland Science, 2002. – 1615 p.207184. Molecular consequences of cystic fibrosis transmembrane regulator genemutations in the exocrine pancreas / N. Ahmed, M.
Corey, G. Forstner, J. Zielenski,L.C. Tsui, L. Ellis, E. Tullis, P. Durie // Gut. – 2003. – Vol. 52, № 8. – P. 11521164.185. Mononuclear phagocytes and airway epithelial cells: novel sources ofmatrix metalloproteinase-8 (MMP-8) in patients with idiopathic pulmonary fibrosis /V.J. Craig, F. Polverino, M.E. Laucho-Contreras, Y. Shi, Y. Liu, J.C.
Osorio, Y.Tesfaigzi, V. Pinto-Plata, B.R. Gochuico, I.O. Rosas, C.A. Owen // PLoS One. – 2014.– Vol. 9, № 5. – e97485.186. Mosca, M. A case of undifferentiated connective tissue disease: is it adistinct clinical entity? / M. Mosca, C. Tani, S. Bombardieri // Nat. Clin. Pract.Rheumatol. – 2008. – Vol. 4, № 6. – P. 328-332.187. Mosca, M. Defining undifferentiated connective tissue diseases: achallenge for rheumatologists / M. Mosca, C. Tani, S. Bombardieri // Lupus. – 2008.– Vol.
17, №4. – P. 278-280.188. Nagase, H. Proteinases and matrix degradation / H. Nagase, Y. Okada //In: Textbook of Rheumatology. Kelley W. (ed). – WB Saunders, Philadelphia, 1997. –P. 323-341.189. Neonatal screening for cystic fibrosis. Results of 10 years / V.D. Sherman,E.I. Kondratieva, N.Yu.
Kashirskaya, S.G. Kalinenkova, Yu.Yu. Kotalevskaya // NewTechnologies for the Diagnosis of Hereditary Diseases: The Second All-RussianScientific and Practical Conference. – M., 2017. – Р. 109-111190. Nicole, S. Perlecan, the major proteoglycan of basement membranes, isaltered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia) / S.Nicole, C.S.
Davoine, H. Topaloglu // Nat. Genet. – 2000. – Vol. 26, № 4. – P. 480483.191. Nitric oxide synthase and heme oxygenase expressions in human livercirrhosis / B.J. Goh, B.T. Tan, W.M. Hon, K.H. Lee, H.E. Khoo // World J.Gastroenterol. – 2006. – Vol. 12, № 4. – P. 588-594.208192. Nutrition in patients with cystic fibrosis: a European Consensus / M.Sinaasappel, M.
Stern, J. Littlewood, S. Wolfe, G. Steinkamp, H.G. Heijerman, E.Robberecht, G. Döring // J. Cyst.Fibros. – 2002. – Vol.1, № 2. – Р.51-75.193. Official ERS/ATS clinical practice guidelines: noninvasive ventilation foracute respiratory failure / B. Rochwerg, L. Brochard, M.W. Elliott, D. Hess, N.S. Hill,S. Nava, P. Navalesi, M. Antonelli, J. Brozek, G. Conti, M.
Ferrer, K. Guntupalli, S.Jaber, S. Keenan, J. Mancebo, S. Mehta, S. Raoof // Eur. Respir. J. – 2017. – Vol. 50(2). – Р. 34-37194. O'Riordan, S.M. Cystic fibrosis-related diabetes in childhood / S.M.O'Riordan, M.T. Dattani, P.C. Hindmarsh // Horm Res Paediatr. – 2010. – Vol. 73, №1. – P.15-24.195. Otrock, Z.K. Vascular endothelial growth factor family of ligands andreceptors: review / Z.K.
Otrock, J.A. Makarem, A.I. Shamseddine // Blood Cells Mol.Dis. – 2007. – Vol. 38, № 3. – P. 258-268.196. Owen, C.A. The cell biology of leukocyte-mediated proteolysis / C.A.Owen, E.J. Campbell // J. Leukoc. Biol. – 1999. – Vol. 65, № 2. – P. 137-150.197. Pettit, R.S. CFTR Modulators for the Treatment of Cystic Fibrosis / R.S.Pettit, C.
Fellner // РТ. – 2014. – Vol. 39(7). – Р. 500-511.198. Polgar, G. Pulmonary function testing in children: techniques andstandards. / G. Polgar, V. Promadhat. – Philadelphia: WB Saunders, 1971. – 211 р.199. Polymorphisms of TGF-beta1 in cystic fibrosis patients / J. Brazova, K.Sismova, V. Vavrova, J. Bartosova, M. Jr Macek, H. Lauschman, A. Sediva // Clin.Immunol. – 2006.
– Vol. 121, № 3. – P. 350-357.200. Progressive divergent shifts in natural and induced T-regulatory cellssignify the transition from undifferentiated to definitive connective tissue disease / P.Szodoray, B. Nakken, S. Barath, J. Gaal, M. Aleksza, M. Zeher, S. Sipka, A. Szilagyi,E. Zold, G. Szegedi, E. Bodolay // Int. Immunol.
– 2008. – Vol. 20, № 8. – P. 971979.201. Pulmonary disease in patients with Marfan syndrome / J.R. Wood, D.Bellamy, A.H. Child, K.M. Citron // Thorax. – 1984. – Vol. 39, № 10. – P. 780-784.209202. Recurrent ctb(7)(q31.3) and possible laminin involvement in a neonatalcutis laxa with a Marfan phenotype / D. Bonneau, J.L. Huret, G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
